Bone Marrow Purging for Autologous Bone Marrow Transplantation

References

• Ball E. D., Mills L. E., Cornwell G. G., Davis B. H., Coughlin C. T., Howell A. L., Stukel T. A., Dain B. J., McMillan R., Spruce W., Miller W. E., Thompson L. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody bone marrow. Blood 1990; 75: 1199–1206
   PubMed Web of Science ®Google Scholar
• Armitage J. 0. Bone Marrow Transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749–1758
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C., Mauch P., Rabinowe S. N., Blake K., Yeap B., Soiffer R., Coral F., Heflin L., Ritz J., Nadler L. M. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J. Clin. Oncol. 1990; 8: 1–8
   PubMedGoogle Scholar
• Gribben J. G., Goldstone A. H., Linch D. C., Taghipour G., McMillan A. K., Sauhami R. I., Earl H., Richards J. D. M. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional dose therapy. J. Clin. Oncol. 1989; 7: 1621–1629
   PubMed Web of Science ®Google Scholar
• Hurd D. D., LeBien T. W., Lasky L. C., Haake R. J., Ramsay N. K. C., Kim T. H., Levine E. G., McGlave P. B., Bloomfield C. D., Peterson B. A., Kersey J. H. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am. J. Med. 1988; 85: 829–834
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J.P., Maraninchi D., Pico J., Bosly A., Andersonn C., Schots R., Biron P., Cabanillas F., Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Linch D. C., Singer C. R. J., McMillan A. K., Jarrett M., Goldstone A. H. Successful treatment of refractory Hodgkin's disease by high dose chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344
   PubMed Web of Science ®Google Scholar
• Cleary M. L., Chao J., Wanke R., Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B cell lymphoma. Proc. Natl. Acad. Sci. USA 1984; 81: 593–597
   PubMed Web of Science ®Google Scholar
• Berliner N., Ault K., Martin P., Weisberg D. S. Detection of clonal excess in lymphoproliferative disease by kappa/lambda analysis: correlation with immunoglobulin gene DNA arrangements. Blood 1986; 67: 80–85
   PubMed Web of Science ®Google Scholar
• Favrot M., Philip I., Combaret V., Pavone E., Bouffet E., Biron P., Philip T. Monoclonal antibodies and complement purged autograft in Burkitt lymphoma and lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 202–204
   PubMed Web of Science ®Google Scholar
• Sharp J. G., Joshi S. S., Armitage J. O., Bierman P., Coccia P. F., Hamngton D. S., Kessinger A., Crouse D. A., Mann S. L., Weisenberger D. D. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by culture technique. Blood 1992; 79: 1074–1080
   PubMed Web of Science ®Google Scholar
• Estrov Z., Grunberger T., Dube I. D. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N. Engl. J. Med. 1986; 315: 538–542
   PubMed Web of Science ®Google Scholar
• Yunis J. J., Oken M. M., Kaplan M. E., Theologides R. R., Howe A. Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin's lymphoma. N. Engl. J. Med. 1982; 307: 1231–1236
   PubMed Web of Science ®Google Scholar
• Weiss L. M., Warnke R. A., Sklar J., Cleary M. L. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N. Engl. J. Med. 1987; 317: 1185–1189
   PubMed Web of Science ®Google Scholar
• Lee M. S., Blick M. B., Pathak S., Trujillo J. M., Butler J. J., Katz R. L., McLaughlin P., Hagemeister F. B., Velasquez W. S., Goodacre A., et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood 1987; 70: 90–95
   PubMed Web of Science ®Google Scholar
• Crescenzi M., Seto M., Herzig G. P., Weiss P. D., Griffith R. C., Korsmeyer S. J. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc. Natl. Acad. Sci. USA. 1988; 85: 4869–4873
   PubMed Web of Science ®Google Scholar
• Ngan B. Y., Nourse J., Cleary M. L. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759–1762
   PubMed Web of Science ®Google Scholar
• Lee M. S., Chang K. S., Cabanillas F., Freireich E. J., Trujillo J. M., Stass S. A. Detection of minimal residual disease carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175–178
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. F., Woo S. D., Blake K., Shu R. S., Freeman G., Longtine J. A., Pinkus G. S., Nadler L. M. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable bcl-2 translocation have residual cells containing the bcl-2 rearrangement at evaluation and following treatment. Blood 1991; 78: 3275–3280
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A. S., Neuberg D., Roy D. C., Blake K. W., Woo S. D., Grossbard M. L., Rabinowe S. N., Coral F., Freeman G. J., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Kaizer H., Santos G. W., Saral R., Colvin O. M., Stuart R. K., Braine H. G., Burke P. J., Am-Binder R. F., Bums W. H., Fuller D. J., Davis J. M., Karp J. E., Stratford M. W., Rowley S. D., Sensenbrenner L. L., Vogelsang G. B., Wingard J. R. Autologous bone marrow transplantation in patients with acute myelogenous leukemia using ex vivo marrow treatment with 4 hydroxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Aegerter P., Auvert B., Meloni G., Goldstone A. H., Burnett A., Carella A., Korbling M., Herve P., Maraninchi D., Lowenberg R., Verdonck L. F., de Planque M., Hermans J., Helbig W., Porcellini A., Rizzoli V., Alesandrino E. P., Franklin I. M., Reiffers J., Colleselli P., Goldman J. M. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European Survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Roy D. C., Felix M., Cannady W. G., Cannistra S., Ritz J. Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk. Res. 1990; 14: 407–416
   PubMed Web of Science ®Google Scholar
• Trickett A. E., Ford D. J., Lam-Po-Tang P. R. L., Vowels M. R. Immunomagnetic bone marrow purging of common acute lymphoblastic leukemia cells: suitability of BioMag particles. Bone Marrow Transplant 1991; 7: 199–203
   PubMed Web of Science ®Google Scholar
• Bast R. C., De Fabritiis P., Lipton J., Geiber R., Maver C., Nadler L. M., Sallan S., Ritz J. Elimination of malignant clonogenic cells from human bone marrows using multiple monoclonal antibodies and complement. Cancer Res. 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• LeBien T. W., Stepan D. E., Bartholomew R. M., Strong R. C., Anderson J. M. Utilization of a colony assay to assess the variables influencing elimination of leukemic cells from human bone marrow with monoclonal antibodies and complement. Blood 1985; 65: 945–950
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Bregni M., Lipton J., Greenberger J., Nadler L., Rothstein L., Korbling M., Ritz J., Bast R. C. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4–hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 1985; 65: 1064–1070
   PubMed Web of Science ®Google Scholar
• Negrin R. S., Kiem H. P., Schmidt-Wolf I. G. H., Blume K. G., Cleary M. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. Blood 1991; 77: 654–660
   PubMed Web of Science ®Google Scholar
• Treleaven J., Gibson F., Udelstad J. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microsphere. Lancet 1984; ii: 70–76
   Google Scholar
• Kvalheim G., Sorensen O., Fodstad O., Funderud S., Kiesel S., Dorken B., Nustad K., Jakobsen E., Ugelstad J., Pihl A. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988; 3: 31–41
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Saporito L., Barber M., Blake K. W., Edwards R. M., Freedman A. S., Nadler L. M. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of PCR detectable lymphoma cells using monoclonal antibodies and immunomagnetic beads. Blood 1992; 80: 1083–1089
   PubMed Web of Science ®Google Scholar
• FitzGerald D. J., Willingham M. C., Cardarelli C. O., Hamada H., Tsuruo T., Gottesman M. M., Pastan I. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 1987; 84: 4288–4292
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Nadler L. M. Immunotoxin Therapy of Malignancy. Important Advances in Oncology, V. T. De Vita, S. Hellamn, S. A. Rosenberg. Lippincott, J.B., Philadelphia 1992; 111–135
   Google Scholar
• Strong R. C., Uckun F., Youle R. J., Kersey J., Vallera D. A. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 1985; 66: 627–635
   PubMed Web of Science ®Google Scholar
• Montgomery R. B., Kurtzberg J., Rhinehardt-Clark A., Haleen A., Ramakrishan S., Olsen G. A., Peters W. P., Smith C. A., Haynes B. F., Houston L. L., Bast R. C. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2′-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 1990; 5: 395–402
   PubMed Web of Science ®Google Scholar
• De Fabritiis P., Ferrero D., Sandrelli A., Tarella C., Meloni G., Pulsoni A., Pregno P., Badoni R., De F. L., Gallo E., et al. Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transplant 1989; 4: 669–674
   PubMed Web of Science ®Google Scholar
• Robertson M. J., Soiffer R. J., Freedman A. S., Rabinowe S. N., Anderson K. C., Ervin T. J., Murray C., Dear K., Griffin J. D., Nadler L. M., Ritz J. Human bone marrow depleted of CD33–positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of My9 monoclonal antibody-purged autigrafts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229–2236
   PubMed Web of Science ®Google Scholar
• Simonsson B., Burnett A. K., Prentice H. G., Hann I. H., Brenner M. K., Gibson B., Grob J. P., Lonnerholm G., Morrison A., Smedmyr B., et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3: 631–636
   PubMed Web of Science ®Google Scholar
• Combaret V., Favrot M. C., Chauvin F., Bouffet E., Philip I., Philip T. Immunomagnetic depletion of malignant cells from autologous bone marrow graft: from experimental models to clinical trials. J. Immunogenet. 1989; 16: 125–136
   PubMedGoogle Scholar
• Philip T., Bernard J. L., Zucker J. M., Pinkerton R., Lutz P., Bordigoni P., Plouvier E., Robert A., Carton R., Philippe N., et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J. Clin. Oncol. 1987; 5: 266–271
   PubMed Web of Science ®Google Scholar
• Kemshead J. T., Treleaven J., Heath L., Meara A. O., Gee A., Ugelstad J. Monoclonal antibodies and magnetic microspheres for the depletion of leukemic cells from bone marrow harvested for autologous transplantation. Bone Marrow Transplant 1987; 2: 133–139
   PubMed Web of Science ®Google Scholar
• Preijers F. W. M. B., De Witte T., Wessels J. M. C., De Gast G. C., Van Leewen E., Capel P. J. A., Haanen C. Autologous transplantation of bone marrow purged in vitro with anti-CD7–(WT1–) rich A immunotyoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152–1158
   PubMed Web of Science ®Google Scholar
• Uckun F., Kersey J. H., Vallera D. A., Ledbetter J. A., Weisdorf D., Myers D. E., Kaake R., Ramsey N. K. C. Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4–hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–1733
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Andrews R. G., Bensinger W. I. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J. Clin. Invest. 1988; 81: 951–955
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Bensinger W. I., Hill R. S. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722
   PubMed Web of Science ®Google Scholar